When Sonny's life was hanging in the balance at just one year old, his family was hoping for a miracle. Shortly after he was ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage liver disease.

US FDA approves Jazz Pharma’s Ziihera to treat adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer: Dublin Friday, November 22, 2024, 1 ...

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...

GlobeNewswire, Health, Pharmaceuticals & Biotechnology, Product / Services Announcement | Ziihera is the first and only dual HER2-targeted bispecific ...

Science 37 (SNCE) was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical ...

William Blair has the equivalent of a buy rating on the stock, as do all 13 analysts offering coverage of the stock on FactSet. The bank is one of many expecting Viking to be a takeover target, given ...